ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the appointment of Wendy Sanhai, Ph.D., MBA, to its Board of Directors. A trusted advisor to Fortune 500 pharmaceutical, biotechnology, and medical device companies, Dr. Sanhai’s appointment further positions ELIQUENT to meet the growing global demand for integrated regulatory, quality, and safety solutions across diverse markets.
“We are thrilled to welcome Dr. Sanhai to ELIQUENT’s Board of Directors,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences. “Her deep understanding of the scientific, clinical, and regulatory landscapes, paired with her strategic expertise at both the board and C-suite levels, will be a catalyst for sustainable growth and lasting impact.”
A distinguished life sciences leader and scientific expert, Dr. Sanhai’s professional background spans roles in academia, regulated industry, and senior positions at the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH). As the former Senior Scientific Advisor in the Office of the Commissioner at the U.S. FDA, she spearheaded strategic initiatives to advance medical product development, bridge public health gaps, and improve patient care. During her tenure as Director of Public-Private Partnerships at the Foundation for NIH, Dr. Sanhai led collaborations with industry and external stakeholders to further NIH’s mission of advancing research and improving health outcomes.
In private industry, Dr. Sanhai served as Senior Director at GlaxoSmithKline (GSK), where she worked across therapeutic areas and international business units to accelerate drug development and achieve organizational objectives. Most recently, at Deloitte Consulting LLC, she advised senior leaders across NIH, FDA, the Department of Defense, the Veterans Health Administration, and multiple life sciences Fortune 500 companies in crafting innovative solutions and driving operational efficiencies in public health, medical product development, and regulatory strategies.
Dr. Sanhai currently serves as a Board member on several organizations, including the Medicines for Malaria Ventures (MMV), University of Maryland Board of Trustees and the Advisory Board of the Robert H. Smith School of Business, and a member of the Burroughs Wellcome Fund Innovation in Regulatory Science, Advisory Committee. She is a Visiting Professor of Practice and Executive in Residence at the University of Maryland, Robert H. Smith School of Business and an Associate Professor (adjunct) at Duke School of Medicine.
Dr. Sanhai earned her PhD in clinical biochemistry from the State University of New York at Buffalo, an MBA from the University of Maryland, and a BS from the University of Florida.
About ELIQUENT Life Sciences
ELIQUENT redefines regulatory consulting with a full-service platform that delivers integrated solutions across the product lifecycle. The firm's unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards. ELIQUENT's platform of regulatory solutions feature the following integrated service offerings:
- Regulatory Affairs Solutions: From the earliest phases of innovation through regulatory submissions, to post- approval support, ELIQUENT guides companies to approval and beyond.
- Pharmacovigilance & Risk Management Solutions: With an approach that includes both strategic direction and hands-on global support, customized PV solutions empower companies to operate with confidence.
- Quality & Compliance Solutions: Highly specialized compliance experts build customized solutions that equip companies with best- in-class strategic support, technical expertise, and project-based solutions.
- Remediations Solutions: Respected professionals and global experts bring an unmatched level of credibility and trust when interacting with regulators and guiding companies to remediation solutions.
- Talent Solutions: Whether you need a team of one or 100+, ELIQUENT’s talent solutions gives clients the ability to rapidly scale teams to the right size, with the right level of expertise, in the right locations.
ELIQUENT Life Sciences was established by uniting the expertise of six premier consultancies — Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC — into a single, globally integrated organization. THE ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.
Learn more about ELIQUENT Life Sciences at eliquent.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113632074/en/
Contacts
Taryn Fritz Walpole
twalpole@eliquent.com
